04:27 AM EDT, 05/30/2024 (MT Newswires) -- Merus (MRUS) said late Wednesday it priced a public offering of about 7.6 million common shares at $53 per share.

The gross proceeds from the offering are expected to total about $400.2 million.

The oncology-focused biopharmaceutical company said it granted underwriters of the offering a 30-day option to purchase up to around 1.1 million additional shares.

The company said it intends to use net proceeds to finance clinical advancement of its potential therapies, develop technology, and for general corporate purposes.

Price: 53.10, Change: -0.90, Percent Change: -1.67